Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have earned a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $24.25.

A number of brokerages have issued reports on ARCT. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. Wall Street Zen raised shares of Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 18th.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ARCT. ARK Investment Management LLC grew its position in Arcturus Therapeutics by 39.4% during the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock valued at $16,006,000 after buying an additional 738,378 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Arcturus Therapeutics by 12.9% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,671,000 after acquiring an additional 262,347 shares during the period. Amova Asset Management Americas Inc. boosted its stake in shares of Arcturus Therapeutics by 12.9% during the 1st quarter. Amova Asset Management Americas Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,648,000 after acquiring an additional 262,347 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Arcturus Therapeutics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,885,605 shares of the biotechnology company’s stock worth $34,752,000 after acquiring an additional 75,440 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of Arcturus Therapeutics by 112.0% during the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after acquiring an additional 327,626 shares during the period. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Stock Down 1.0%

Shares of ARCT stock opened at $5.93 on Thursday. The stock has a market cap of $168.55 million, a PE ratio of -2.11 and a beta of 2.37. The business has a 50-day simple moving average of $7.08 and a 200-day simple moving average of $7.47. Arcturus Therapeutics has a 52-week low of $5.77 and a 52-week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Friday, May 8th. The biotechnology company reported ($0.95) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.08. The firm had revenue of $2.06 million for the quarter, compared to the consensus estimate of $6.30 million. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%. Sell-side analysts anticipate that Arcturus Therapeutics will post -3.99 earnings per share for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.